Dr. Cosme Ordoñez Appointed Head of Investment
Banking
NEW
YORK, March 12, 2024 /PRNewswire/ -- Dominari
Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced
its wholly-owned subsidiary, Dominari Securities LLC, has appointed
Dr. Cosme Ordoñez to the role of Head of Investment Banking,
Investment Banking Principal and bolstering the firm's coverage in
the healthcare sector.
Dr. Ordoñez has more than 20 years of investment banking and
healthcare experience. Most recently, he served as Senior Managing
Director, Investment Banking at Aegis Capital in its private equity
group.
Mr. Kyle Wool, CEO of Dominari
Securities LLC, commented, "We are thrilled to welcome Cosme to the
firm to head up our investment banking practice. Over the course of
his distinguished career, he has gained extensive experience with
corporate finance activities, financial advisory services and
capital raising having managed a portfolio in excess of
$100 million and raised nearly a
billion dollars in capital for life science companies. Furthermore,
with his medical scientific background, Dr. Ordoñez will be a
tremendous asset to our clients in healthcare. We are pleased to
welcome Cosme to Dominari."
Dr. Cosme Ordoñez
Dr. Ordoñez began his career as a Doctor of Medicine at the
National Institute of Oncology in Havana,
Cuba where he researched the amplification of oncogenes in
breast cancer. With deep industry knowledge, he transitioned to
investment banking more than 20 years ago as a healthcare analyst
at Versant Partners, which was later acquired by Cantor Fitzgerald.
Most recently, at Aegis Capital, he acted as the lead investment
banker in multiple private placement transactions and as the
Manager of a portfolio of investments in private equity valued at
more than $100 million.
Over the course of his career, Dr. Ordoñez has acted as the lead
investment banker in multiple transactions, leading deal
origination, due diligence, corporate finance advisory, valuation
modeling, syndication and deal execution through sales and
marketing efforts in collaboration with equity capital markets
desks. Dr. Ordoñez was the co-founder of Ciclofilin
Pharmaceuticals, a startup biotech based in San Diego, which was acquired in 2016. Prior
to founding Ciclofilin Pharma, Dr. Ordoñez worked on the buy-side
as Director of Healthcare Investments at Difference Capital, a
venture capital and merchant bank, where he participated in
investment decisions for a portfolio of international private and
public healthcare companies. Previously, he was a senior
biotechnology analyst at two other independent Canadian investment
dealers, where he achieved top rankings for perceived quality of
research by Brendan Wood International and Starmine.
Dr. Ordoñez has a Doctor in Medicine degree, a Ph.D. in
Experimental Medicine and Biochemistry from McGill University. He also completed a
Post-Doctoral Fellowship at the Karolinska
Institute in Stockholm,
Sweden. Dr. Ordoñez has published scientific manuscripts in
the areas of oncology, virology and immunology. He currently holds
Series 79, 7, 86 and 87 FINRA licenses.
For additional information about Dominari Holdings Inc., please
visit: https://www.dominariholdings.com/
Dominari Securities LLC's Mission Statement:
Dominari Securities LLC, a principal subsidiary of Dominari
Holdings Inc., is a dynamic, forward-thinking financial services
company that seeks to create wealth for all stakeholders by
capitalizing on emerging trends in the financial services sector
and identifying early-stage future opportunities that are expected
to generate a high rate of return for investors.
Securities Brokerage and Registered Investment Adviser Services
are offered through Dominari Securities LLC, a Member of FINRA,
MSRB and SIPC. Securities brokerage, investment adviser and other
non-bank deposit investments are not FDIC insured and may lose
some or all of the principal invested. You can check the background
of Dominari Securities and its registered investment professionals
and review its SEC Form CRS on FINRA's BrokerCheck site at
https://brokercheck.finra.org. Information for Dominari Securities
LLC and its registered investment professionals as well as its SEC
Form CRS may also be found on FINRA's BrokerCheck site.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
which include but are not limited to the Risk Factors set forth in
the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2022 relating to its
business. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contacts:
Dominari Holdings
Inc.
https://www.dominariholdings.com/
Investor Relations
Hayden IR
Brett Maas,
Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dominari-securities-llc-expands-investment-banking-practice-with-appointment-of-experienced-financial-executive-302085399.html
SOURCE Dominari Holdings Inc.
